Neonatal Sepsis Clinical Trial
Official title:
Role of Prophylactic Antibiotics in Preventing Neonatal Sepsis in Neonates Born Through Meconium Stained Amniotic Fluid - A Randomized Controlled Trial
The purpose of the study is to evaluate the role of antibiotics in preventing infection in babies born through meconium stained amniotic fluid. Normally babies do not pass meconium while in utero. In response to hypoxic stress babies may pass meconium before birth and are likely to be candidates for problems related to meconium passage and its inhalation. It is believed that these babies are more prone to infections as meconium enhances bacterial growth and may predispose such babies to secondary bacterial infections. In addition, meconium passage has been incriminated as a pointer of in-utero infection. Whether use of antibiotics in babies born through meconium stained amniotic fluid will reduce the infectious episodes and complications thereof or not is not clear. Moreover, there is not much published literature to prove or refute the same. Most clinicians have a low threshold for using antibiotics in such babies. In view of the uncertainty regarding antibiotic usage in these babies, the investigators decided to investigate the role of prophylactic antibiotics in prevention of neonatal sepsis in babies born through meconium stained amniotic fluid.
Meconium passage in newborn infants is a developmentally programmed event normally occurring
within first 24-48 hours of birth. Intra uterine meconium passage in near term or term
fetuses has been associated with feto-maternal stress factors and/or infections, whereas
meconium passage in post term pregnancies has been attributed to gastro-intestinal maturity.
The meconium staining of amniotic fluid occurs in 12% of all live births per annuum.
Aspiration of meconium that occurs during intra uterine life or after delivery with the
first few breaths may result in or contribute to respiratory pathology known as meconium
aspiration syndrome (MAS) which represents a leading cause of the perinatal morbidity,
occurring in 5-20% of all babies born through MSAF.
The routine use of antibiotics in MSAF babies has been advocated for a long time as a part
of the conventional treatment. Meconium passage in utero is hypothesized to represent a
response to fetal bacterial infection in addition to intrauterine hypoxia. Additionally the
rationale for use of antibiotics includes the radiographic similarity of MAS to bacterial
pneumonia, in vitro enhancement of bacterial growth in presence of meconium as well as the
possibility of meconium induced inhibition of phagocytic activity and respiratory burst
response by alveolar macrophages rendering patients with MAS more susceptible to infection.
These recommendations however are empirical and the incidence of bacterial infection in
neonates born through MSAF as well as in MAS has not been systematically evaluated, to date.
With the rising concern about the emergence of resistant strains in neonatal ICUs and the
possible side effects of antibiotics (like amino glycosides) including nephrotoxicity and
ototoxicity in neonates, a systematically conducted, randomized controlled trial is
necessary to assess the utility of antibiotics in the routine management of infants with
MSAF and MAS. Hence the purpose of this prospective randomized controlled trial is to
compare the clinical course, complications, and infection related outcomes in cases of MSAF
and MAS, treated with or without antibiotics therapy
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05692128 -
Frequency and Severity of Thrombocytopenia in Neonatal Sepsis
|
||
Completed |
NCT00942084 -
A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)
|
Phase 1 | |
Completed |
NCT06002295 -
A Comparative Analysis of 4% Chlorhexidine Versus Methylated Spirit as Prophylaxis of Omphalitis and Sepsis in Newborns
|
Phase 2 | |
Not yet recruiting |
NCT05114057 -
Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI
|
N/A | |
Recruiting |
NCT04528251 -
Comparison of the Effectiveness of Two Different Antibiotic Regimens of the Treatment of Pregnant Women With Preterm Rupture of Membranes
|
||
Active, not recruiting |
NCT03871491 -
Azithromycin-Prevention in Labor Use Study (A-PLUS)
|
Phase 3 | |
Completed |
NCT03746743 -
Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II
|
||
Completed |
NCT02386592 -
Prevention of Nosocomial Bacteremia Among Zambian Neonates
|
N/A | |
Not yet recruiting |
NCT06113653 -
Outcomes and Predictors of Mortality Among Preterm Infants With Neonatal Sepsis
|
||
Completed |
NCT03199547 -
Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death
|
Phase 3 | |
Completed |
NCT02147327 -
Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities
|
N/A | |
Completed |
NCT01005589 -
CD64 Measurement in Neonatal Infection and Necrotising Enterocolitis
|
N/A | |
Completed |
NCT00866567 -
Defects in Opsonophagocytosis in Premature Infants
|
N/A | |
Completed |
NCT02281890 -
Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database
|
N/A | |
Suspended |
NCT05156333 -
Probiotics and GBS Colonization in Pregnancy
|
N/A | |
Recruiting |
NCT05127070 -
Evaluating the NeoTree in Malawi and Zimbabwe
|
||
Completed |
NCT03755635 -
Neonatal Sepsis at Neonatal Intensive Care Units in Ghana
|
N/A | |
Completed |
NCT03247920 -
Reduction of Intravenous Antibiotics In Neonates
|
Phase 4 | |
Completed |
NCT03295162 -
Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis
|
Phase 1/Phase 2 | |
Completed |
NCT02954926 -
Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis
|
Phase 3 |